Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vosoritide in Children with Hypochondroplasia
2024-513129-22-00Phase 3Completed
- Sponsor
- BioMarin Pharmaceutical
- Start
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in hypochondroplasia (HCH) comparing Vosoritide with Placebo (2 arms). Primary endpoint: Change from baseline in annualized growth velocity (AGV) at Week 52. Started Dec 2024; status: completed.
02
Drugs
vosoritide
03
Conditions
hypochondroplasia (HCH)
Beyond the preview
Go deeper on 2024-513129-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513129-22-00.